EPS for Titan Pharmaceuticals, Inc. (TTNP) Expected At $-0.17

February 15, 2018 - By Clifton Ray

 EPS for Titan Pharmaceuticals, Inc. (TTNP) Expected At $ 0.17

Analysts expect Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report $-0.17 EPS on March, 15.They anticipate $0.02 EPS change or 13.33 % from last quarter’s $-0.15 EPS. After having $-0.20 EPS previously, Titan Pharmaceuticals, Inc.’s analysts see -15.00 % EPS growth. It closed at $1.05 lastly. It is down 59.84% since February 15, 2017 and is downtrending. It has underperformed by 76.54% the S&P500.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company has market cap of $22.26 million. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. It currently has negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

More notable recent Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) news were published by: Seekingalpha.com which released: “Titan Pharmaceuticals: Just Be Patient” on July 20, 2017, also Seekingalpha.com with their article: “Titan Pharmaceuticals: What To Look For After Probuphine Approval” published on May 27, 2016, Prnewswire.com published: “Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate …” on July 06, 2017. More interesting news about Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) were released by: Seekingalpha.com and their article: “Titan Pharmaceuticals: Bravery Will Be Rewarded (Just Maybe Not This Year)” published on March 24, 2017 as well as Seekingalpha.com‘s news article titled: “Titan Pharmaceuticals Is About To Pop” with publication date: January 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.